EA200400864A1 - ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ 2-(4-ЭТОКСИФЕНИЛ)-3-(4-МЕТАНСУЛЬФОНИЛФЕНИЛ)ПИРАЗОЛО[1,5-b]ПИРИДАЗИН В ФОРМЕ НАНОЧАСТИЦ - Google Patents

ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ 2-(4-ЭТОКСИФЕНИЛ)-3-(4-МЕТАНСУЛЬФОНИЛФЕНИЛ)ПИРАЗОЛО[1,5-b]ПИРИДАЗИН В ФОРМЕ НАНОЧАСТИЦ

Info

Publication number
EA200400864A1
EA200400864A1 EA200400864A EA200400864A EA200400864A1 EA 200400864 A1 EA200400864 A1 EA 200400864A1 EA 200400864 A EA200400864 A EA 200400864A EA 200400864 A EA200400864 A EA 200400864A EA 200400864 A1 EA200400864 A1 EA 200400864A1
Authority
EA
Eurasian Patent Office
Prior art keywords
nanoparticles
methesulphonylphenyl
etoxyphenyl
pyridazin
pyrazolo
Prior art date
Application number
EA200400864A
Other languages
English (en)
Other versions
EA007201B1 (ru
Inventor
Джонатан Эпплби
Мартин Ролф Хилл
Саймон Джозеф Холланд
Стефани Линн Пирсон
Original Assignee
Глаксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксо Груп Лимитед filed Critical Глаксо Груп Лимитед
Publication of EA200400864A1 publication Critical patent/EA200400864A1/ru
Publication of EA007201B1 publication Critical patent/EA007201B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Данное изобретение предлагает фармацевтическую композицию, содержащую соединение формулы (I) и его фармацевтически приемлемые соли, в которой соединение присутствует в виде твердых частиц в форме наночастиц в смеси с одним или более чем одним фармацевтически приемлемым носителем или эксципиентом.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200400864A 2002-03-15 2003-03-13 ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ 2-(4-ЭТОКСИФЕНИЛ)-3-(4-МЕТАНСУЛЬФОНИЛФЕНИЛ)ПИРАЗОЛО[1,5-b]ПИРИДАЗИН В ФОРМЕ НАНОЧАСТИЦ EA007201B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0206200.8A GB0206200D0 (en) 2002-03-15 2002-03-15 Pharmaceutical compositions
PCT/EP2003/002698 WO2003077920A1 (en) 2002-03-15 2003-03-13 Pharmaceutical compositions comprising 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo’1,5-bipyridazine in nanoparticulate form

Publications (2)

Publication Number Publication Date
EA200400864A1 true EA200400864A1 (ru) 2005-02-24
EA007201B1 EA007201B1 (ru) 2006-08-25

Family

ID=9933079

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200400864A EA007201B1 (ru) 2002-03-15 2003-03-13 ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ 2-(4-ЭТОКСИФЕНИЛ)-3-(4-МЕТАНСУЛЬФОНИЛФЕНИЛ)ПИРАЗОЛО[1,5-b]ПИРИДАЗИН В ФОРМЕ НАНОЧАСТИЦ

Country Status (21)

Country Link
US (1) US20050153967A1 (ru)
EP (1) EP1485098B1 (ru)
JP (1) JP2005520824A (ru)
KR (1) KR20040091133A (ru)
CN (1) CN1642549A (ru)
AT (1) ATE350038T1 (ru)
AU (1) AU2003208709A1 (ru)
BR (1) BR0307427A (ru)
CA (1) CA2478758A1 (ru)
DE (1) DE60310896T2 (ru)
EA (1) EA007201B1 (ru)
EC (1) ECSP045295A (ru)
ES (1) ES2277634T3 (ru)
GB (2) GB0206200D0 (ru)
IS (1) IS7378A (ru)
MX (1) MXPA04009008A (ru)
NO (1) NO20043889L (ru)
NZ (1) NZ534179A (ru)
PL (1) PL372932A1 (ru)
WO (1) WO2003077920A1 (ru)
ZA (1) ZA200406553B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE325115T1 (de) 2002-08-19 2006-06-15 Glaxo Group Ltd Pyrimidinderivate als selektive cox-2-inhibitoren
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
ES2231757T3 (es) * 1997-09-05 2005-05-16 Glaxo Group Limited Composiciones farmaceutica que comprenden derivados de 2,3-diaril-pirazolo (1,5-b) piridazina.
KR100793668B1 (ko) * 1999-12-08 2008-01-10 파마시아 코포레이션 강화된 생체이용률을 지닌 고체상 형태의 셀레콕시브
PT1294358E (pt) * 2000-06-28 2004-12-31 Smithkline Beecham Plc Processo de moagem por via humida

Also Published As

Publication number Publication date
MXPA04009008A (es) 2004-12-07
GB0206200D0 (en) 2002-05-01
IS7378A (is) 2004-07-29
GB2402335B (en) 2005-10-12
ATE350038T1 (de) 2007-01-15
JP2005520824A (ja) 2005-07-14
EP1485098B1 (en) 2007-01-03
ES2277634T3 (es) 2007-07-16
ECSP045295A (es) 2004-10-26
NO20043889L (no) 2004-09-16
AU2003208709A1 (en) 2003-09-29
GB0419971D0 (en) 2004-10-13
CN1642549A (zh) 2005-07-20
KR20040091133A (ko) 2004-10-27
BR0307427A (pt) 2004-12-28
DE60310896T2 (de) 2007-05-10
EP1485098A1 (en) 2004-12-15
GB2402335A (en) 2004-12-08
PL372932A1 (en) 2005-08-08
DE60310896D1 (de) 2007-02-15
NZ534179A (en) 2006-07-28
CA2478758A1 (en) 2003-09-25
US20050153967A1 (en) 2005-07-14
WO2003077920A1 (en) 2003-09-25
ZA200406553B (en) 2005-09-22
EA007201B1 (ru) 2006-08-25

Similar Documents

Publication Publication Date Title
EA200100972A1 (ru) Новые соединения и композиции как ингибиторы протеаз
TNSN03110A1 (en) Azaindoles.
EA200201179A1 (ru) Производные 2-аминокарбонил-9h-пурина
BG108650A (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
EA200400073A1 (ru) Пирролопиримидины как ингибиторы протеинкиназы
DE602004008098T8 (de) Substituierte 2h-[1,2,4]triazolo[4,3-a]pyrazine als gsk-3-inhibitoren
HK1089163A1 (en) Quinoxaline derivatives as neutrophil elastase inhibitors and their use
EA200200938A1 (ru) Фармацевтические композиции, содержащие производные азетидина, новые производные азетидина и их получение
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
NO20062098L (no) Faststofftilstandmontelukast
EA200500814A1 (ru) Производные пирролопиримидина
IL187438A0 (en) Pyrrolopyridine derivatives and pharmaceutical compositions containing the same
CY1111693T1 (el) Αντιιικοι παραγοντες
DE60324544D1 (de) Muskarin antagonisten
AU2003250471A8 (en) Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
DE60301339D1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
SE0102055D0 (sv) New Compounds
EA200301203A1 (ru) Новые соединения и композиции как ингибиторы катепсина
WO2003053971A8 (en) Pyridoquinoxaline antivirals
AR044175A1 (es) Compuestos de cefemo
EA200100984A1 (ru) Новые кристаллические формы макролидного антибиотика
EA200400864A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ 2-(4-ЭТОКСИФЕНИЛ)-3-(4-МЕТАНСУЛЬФОНИЛФЕНИЛ)ПИРАЗОЛО[1,5-b]ПИРИДАЗИН В ФОРМЕ НАНОЧАСТИЦ
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
DE69827614D1 (de) Chinoxalindionen
EA200702457A1 (ru) (5z)-5-(6-хиноксалинилметилиден)-2-[(2,6-дихлорфенил)амино]-1,3-тиазол-4(5h)-он

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KG